BioCentury
ARTICLE | Finance

Neurogastrx: $60M crossover round to advance de-risked GI assets

Emerging Company Profile: Funding, assist from Vivo to land Phase III-ready Daewoong asset readies biotech to build on its CEO’s Ironwood roots

August 26, 2021 10:58 PM UTC

A June deal that came together through Vivo Capital brought a Phase III-ready asset into the hands of Neurogastrx, complementing an existing gastrointestinal program and an executive team with ...



Access this Article